OPTINOSE
OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal "Bi-Directional Delivery" which allows drugs to be more efficiently delivered to the nasal cavity. By applying its drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices. The OptiNose delivery devices have high d... ose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a faster onset of action, greater effect with a lower dose, and reduced side effects. The company has offices in Norway and the UK.
OPTINOSE
Social Links:
Industry:
Biotechnology Medical Device Pharmaceutical
Founded:
2000-01-01
Address:
Oslo, Oslo, Norway
Country:
Norway
Website Url:
http://www.optinose.com
Total Employee:
101+
Status:
Active
Contact:
267-364-3500
Total Funding:
401.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aprecia Pharmaceuticals
Aprecia Pharmaceuticals develops precision drug delivery systems and products.
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
FGen
FGen develops proprietary technologies and products in different biotechnological areas.
Myomo
Myomo develops devices with myoelectric prosthetic technology to restore the mobility of individuals with muscle weakness.
OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Pharmakon Advisors
Pharmakon Advisors investment in Post-IPO Debt - OptiNose
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series D - OptiNose
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series D - OptiNose
Entrepreneurs Fund
Entrepreneurs Fund investment in Series D - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series C - OptiNose
The Entrepreneurs' Fund
The Entrepreneurs' Fund investment in Series C - OptiNose
WFD Ventures
WFD Ventures investment in Series C - OptiNose
Avista Capital Partners
Avista Capital Partners investment in Series C - OptiNose
Entrepreneurs Fund
Entrepreneurs Fund investment in Series C - OptiNose
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-03 | Optinose Announces Departure of Chief Financial Officer |
Official Site Inspections
http://www.optinose.com Semrush global rank: 2.7 M Semrush visits lastest month: 6.13 K
- Host name: 20.119.8.33
- IP address: 20.119.8.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "OptiNose"
Leadership Team - Optinose
OptiNose - Crunchbase Company Profile & Funding
The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown that devices can provide a …See details»
Our Company - Optinose
The innovative mechanism of action of the first Optinose technology is designed to enable broad, consistent drug delivery high and deep in the nasal passages, leveraging the mucosal …See details»
Optinose - LinkedIn
Optinose | 5,859 followers on LinkedIn. ... Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the ...See details»
OptiNose - Contacts, Employees, Board Members, Advisors
Organization. OptiNose . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 7. Number of Board …See details»
OptiNose, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Optinose Investor Contact Jonathan [email protected] ### Clinical Result Drug Approval. 28 Aug 2024 ... The statistics for drugs in the Pipeline is the …See details»
OptiNose Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 OptiNose has 4 employees across 3 locations and $70.99 m in annual revenue in FY 2023. See insights on OptiNose including office locations, competitors, revenue, financials, …See details»
OptiNose - Funding, Financials, Valuation & Investors - Crunchbase
OptiNose is registered under the ticker NASDAQ:OPTN . Their stock opened with $16.00 in its Oct 13, 2017 IPO. Stock Symbol NASDAQ:OPTN ; Valuation at IPO $604M; Money Raised at …See details»
Committee Composition | Optinose
The Investor Relations website contains information about Optinose's business for stockholders, potential investors, and financial analysts.See details»
Working At Optinose: Company Overview and Culture - Zippia
Learn about working at Optinose from employee reviews and detailed data on culture, salaries, demographics, management, financial, and more. ... Organization Type. Public. Social Media. …See details»
Optinose Company Overview, Contact Details & Competitors
May 9, 2024 Recent Expansion Optinose has received $55 million in financing to boost the commercialization of XHANCE, ... Culture is a critical element in the management of our …See details»
Our Purpose - Optinose
The Optinose team is unified by a common shared mission: to improve lives. We will accomplish this while creating value for investors and the healthcare system along with better outcomes …See details»
OptiNose Company Information - Funding, Investors, and More
OptiNose Unknown (2022, $50M) $50m. 2024. OptiNose Seed (2002, $0M) $601k. Discover Iwoca. Company size. 101 - 251. Founding Rounds. 3. Investors. 5. Money raised. 99.1m. …See details»
Optinose Announces Changes to Board of Directors
Dec 1, 2020 Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn …See details»
Optinose Reports Fourth Quarter and Full Year 2023 Financial …
Dec 31, 2023 In addition, during 2023 we worked hard to prepare our organization to make the most of the new opportunity. We revised operations in a variety of ways to better support a …See details»
OptiNose, Inc. | Insights
Nov 21, 2022 OptiNose UK Ltd. OptiNose US, Inc. See more in Biomedtracker. Latest on OptiNose, Inc. Already A Biomedtracker Subscriber? You have access to the full company …See details»
Company History - Optinose
The application (now approved) included clinical data showing that Optinose significantly improved headache relief within 30 minutes using a very low dose of medication. To help …See details»
Former Optinose CEO comes out of retirement to launch new …
Dec 1, 2024 It turns out former Optinose CEO Peter Miller wasn't as ready for retirement as he thought. Last year, Peter Miller was ready to retire. "I was going to put 'grandfather' in the job …See details»
Board of Directors - Optinose
Board of Directors. R. John Fletcher. R. John Fletcher, age 77, founded Fletcher Spaght Inc., a strategy consulting and venture capital firm, in 1983 and as its managing partner emeritus, …See details»
OptiNose (OPTN) Earnings Date and Reports 2025 - MarketBeat
Nov 20, 2024 Get the Latest News and Ratings for OPTN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for OptiNose and its …See details»